BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20200308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20201101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20210314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20211107T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20220313T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20221106T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Indiana/Indianapolis
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210104
DTEND;VALUE=DATE:20210130
DTSTAMP:20260514T021435
CREATED:20201215T003656Z
LAST-MODIFIED:20201215T004101Z
UID:1661-1609718400-1611964799@thebiocalendar.com
SUMMARY:JPM MONTH - Get the premier guide\, On Your Mark 2021
DESCRIPTION:January 2021\, the Month of the J.P. Morgan Healthcare Conference\n\nSAN FRANCISCO\, CA–(December 14\, 2020)–Big4Bio\, the leading news aggregator service for the top biotech hubs in the United States\, proudly announces the publishing of the 5th edition of On Your Mark\, a compendium of virtual investor and partnering events revolving around the 39th Annual J.P. Morgan Healthcare Conference (#JPM2021). \n“Due to COVID-19 and all events moving to virtual\, what is usually ‘JPM Week’ is essentially ‘JPM Month” for 2021\,” says Tilton Little\, publisher of Big4Bio. “No longer restricted by space\, costs\, and other constraints\, organizations are using the entire month to cater to a diverse audience of industry stakeholders worldwide\, with the J.P. Morgan Healthcare Conference right in the center of everything.” \n“Attending these events is a must for many in the business of biopharma and healthcare\,” says Tilton Little\, publisher of Big4Bio. “From the ACCESS CHINA sessions beginning January 4 to MassBio’s inaugural ‘Partnering Week’ on January 25-29\, this year’s special ‘JPM Month’ has something for everyone in the industry\, and ‘On Your Mark’ will assist all attendees in this brave new virtual world.” \nDOWNLOAD ON YOUR MARK 2021 NOW
URL:https://thebiocalendar.com/event/jpm-month-get-the-premier-guide-on-your-mark-2021/
LOCATION:PA
CATEGORIES:Featured
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2020/12/oym2021cover.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210125
DTEND;VALUE=DATE:20210128
DTSTAMP:20260514T021435
CREATED:20201111T002115Z
LAST-MODIFIED:20201111T002117Z
UID:1363-1611532800-1611791999@thebiocalendar.com
SUMMARY:PMWC COVID
DESCRIPTION:The COVID-19 pandemic makes it necessary for leading experts from across disciplines and geographies to come together to jointly address the challenges we are facing when coping with the disruptive nature of the coronavirus SARS-CoV-2 pandemic is having on our healthcare system and our society as a whole. The tasks upon us are enormous and include besides decoding the virus and scaling diagnostics\, tackling COVID-19 within existing healthcare systems\, building health data platforms that support COVID-19 focused health care\, accommodating clinical trials in the era of COVID-19\, and developing functional vaccines and therapeutics. The next PMWC 2021 on January 25-27 would be a virtual conference and will touch upon these critical developments and ongoing activities while also including the regulatory and investment sides that influence clinical advancements.
URL:https://thebiocalendar.com/event/pmwc-covid/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210126T080000
DTEND;TZID=UTC:20210126T170000
DTSTAMP:20260514T021435
CREATED:20210127T062510Z
LAST-MODIFIED:20210127T062528Z
UID:1710-1611648000-1611680400@thebiocalendar.com
SUMMARY:Oscar
DESCRIPTION:Prueba
URL:https://thebiocalendar.com/event/oscar/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210126T094500
DTEND;TZID=UTC:20210128T170000
DTSTAMP:20260514T021435
CREATED:20210125T160000Z
LAST-MODIFIED:20201029T195935Z
UID:740-1611654300-1611853200@thebiocalendar.com
SUMMARY:Pharmacovigilance and Risk Management Strategies Conference
DESCRIPTION:DIA’s Pharmacovigilance and Risk Management Strategies Conference provides the foundation for strong strategic planning and practical decision-making in your pharmacovigilance programs. Developed by recognized experts from the biopharmaceutical industry and global regulatory agencies\, this conference provides the background\, context\, and opportunities to discuss current challenges and to problem-solve around issues that matter most to professionals working in the field. \nThis year’s conference will address the current thinking on predicting and assessing risks such as drug-induced liver injury\, and the assessment of expectedness of serious adverse reactions during clinical development. The complexities of assessing benefit-risk balance of today’s therapies\, including immunotherapy and other advanced therapies\, will be examined. Experts will present approaches and engage in dialogs around more extensive and impactful uses of real world data and generation of RWE for safety assessments. A full day will be devoted to the development\, implementation\, and assessment of risk management strategies for drugs approved in multiple regions\, with a special in-depth coverage of REMS in the US. \nIn addition to new developments and updates on regional regulations and guidelines\, regulators from the US\, EU\, and other global regions provide the context and thinking behind evolving requirements. \n“One of the best conferences I have attended. A broad view on how far we have come in the world of PV\, why we do what we do\, and what is still to come ot meet future needs of patients and managing benefit-risk.” – Mary Welke\, Trilogy Writing & Consulting\, Inc \n\n\nWho should attend?\nProfessionals with intermediate to advanced knowledge of\, and experience in\, clinical safety and who are involved in: \n\nDrug Safety/Pharmacovigilance\nRisk Management\, including Risk Evaluation and Mitigation Strategies (REMS)\nBenefit-Risk Assessment and Communication\nMedical Product Safety Assessment\nRegulatory Affairs\nClinical Research\nPharmacoepidemiology\nPost-Market Studies and Real World Evidence Generation\nCustomer Engagement Programs\, including Patient Support Programs\nMedical Information\, Medical Communications\nHealth Outcomes\n\nIt is also designed for professionals who work for: \n\nIndustry: Pharmaceuticals\, Biologics\, Combination Products\, Devices\nClinical Research Organizations\, Contract Service Organizations\nAcademic Research Centers\nRegulatory Agencies\nGovernment Research Programs\n\nMembers of board\, C-level\, Senior Vice Presidents\, Vice Presidents\, Directors and Heads of departments from pharmaceutical involved in: \n\nDrug Safety\nPharmacovigilance\nRisk Management\nClinical Safety\nData management and data mining\nSafety & Risk Management\nSignal Detection\nRisk Management\nBenefit-Risk Assessment\nSafety Evaluation\nRegulatory Affairs\, Pharmacovigilance\nPV Governance\nSafety Surveillance\nPharmacovigilance Operations\nPV Inspection and Audit Readiness\nPatient Support Programs\nMarket Research Programs\nMedical Safety\nMedical Information\nPharmacoepidemiology
URL:https://thebiocalendar.com/event/pharmacovigilance-and-risk-management-strategies-conference/
LOCATION:PA
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2020/10/download-6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210126T110000
DTEND;TZID=UTC:20210126T200000
DTSTAMP:20260514T021435
CREATED:20201107T155747Z
LAST-MODIFIED:20201107T155747Z
UID:1277-1611658800-1611691200@thebiocalendar.com
SUMMARY:SV Global Investing Summit--Lifesciences Track
DESCRIPTION:You are invited to sign up and present at the next SV Global Investing Summit –Lifesciences Track on the 26th of January. You can visit pitchglobal.com for more details like the list of hundreds of investing firms which attends this Summit or visit the website of the Event Host\, Dr Fred Cohen\, Founding President of Keiretsu Forum(Pebble Beach Chapter). http://angeltoexit.com/GoToAngel.html
URL:https://thebiocalendar.com/event/sv-global-investing-summit-lifesciences-track/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210209
DTEND;VALUE=DATE:20210211
DTSTAMP:20260514T021435
CREATED:20201107T070358Z
LAST-MODIFIED:20201130T233104Z
UID:1271-1612828800-1613001599@thebiocalendar.com
SUMMARY:Virtual Clinical Trials Summit
DESCRIPTION:Develop a strong protocol\, reduce expected costs\, and increase\npatient participation through the revolution of siteless clinical trials\nBased on the success of our first Virtual Clinical Trials event and the Virtual Clinical Trials Online\, we are pleased to announce the second annual event. This event features unmatched networking opportunities\, presentations\, panels\, and roundtables all developed for smaller companies with limited resources. Join us to gain a comprehensive education on streamlining decentralized clinical trials and the tools and technology needed to enhance patient engagement.
URL:https://thebiocalendar.com/event/virtual-clinical-trials-summit/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2020/11/VCTS-Color.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210209
DTEND;VALUE=DATE:20210212
DTSTAMP:20260514T021435
CREATED:20201108T012735Z
LAST-MODIFIED:20201108T012735Z
UID:1312-1612828800-1613087999@thebiocalendar.com
SUMMARY:Gene Therapy Medical Affairs Summit
DESCRIPTION:The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients. \nIndustry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy\, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs\, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex\, high priced gene therapy products and ultimately work to remove both barriers that exist for access to gene therapies. \nJoin this definitive\, niche conference to delve into the unique Medical Affairs challenges encountered when working with gene therapies\, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch scrutiny\, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before. \nThis virtual event is set to be a highly interactive and engaging meeting. We fully understand (and quite frankly agree) that a presentation-heavy conference just isn’t up to scratch! As such we have created a new format for this meeting which maximises opportunities for engagement\, discussion\, and Q&A’s in order for you to get the best value from this meeting.
URL:https://thebiocalendar.com/event/gene-therapy-medical-affairs-summit/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260514T021435
CREATED:20201108T012046Z
LAST-MODIFIED:20201108T012046Z
UID:1310-1612915200-1613087999@thebiocalendar.com
SUMMARY:12th Annual RNA Therapeutics Virtual Conference
DESCRIPTION:RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines\, and treatment of genetic\, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025\, growing at a CAGR of 7.5%. Furthermore\, the recent advent of CRISPR\, an RNA-guided gene-editing technology\, as well as new strides in the delivery of messenger RNA transcribed in vitro\, have triggered a major expansion of the RNA-therapeutics field. \nThe 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies\, oligonucleotide delivery\, therapeutic applications and future trends and innovations. \nJoin us in February 2021\, as SMi’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry\, upcoming regulatory updates and industry implications.
URL:https://thebiocalendar.com/event/12th-annual-rna-therapeutics-virtual-conference/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260514T021435
CREATED:20201108T012201Z
LAST-MODIFIED:20201108T012201Z
UID:1311-1612915200-1613087999@thebiocalendar.com
SUMMARY:5th Annual Conference 3D Cell Culture
DESCRIPTION:3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years\, with the global 3D Cell Culture market predicted to reach a value of $3.2 Billion by 2027\, researchers globally are realising the growing potential of in vitro applications for drug discovery\, predictivity and validation\, safety and toxicity. \nRising demand for tissue engineering for the treatment of chronic diseases is a key driver of this research and new technologies in the form of organ-on-chip\, microphysiological systems and 3D bioprinting are all significant emerging areas of the field. \nJoin us in February 2021\, as SMi’s 5th annual 3D Cell Culture Conference brings together industry experts from big pharma\, regulatory bodies and the leading biotech companies in the field to discuss the challenges and drivers of the industry\, through case studies of the latest innovations in 3D Cell Culture models\, real world examples of applications of new technologies and insights into 3D imaging and high throughput screening to give you a comprehensive this fast growing industry.
URL:https://thebiocalendar.com/event/5th-annual-conference-3d-cell-culture/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210210T080000
DTEND;TZID=UTC:20210210T170000
DTSTAMP:20260514T021435
CREATED:20201001T215005Z
LAST-MODIFIED:20201001T215005Z
UID:747-1612944000-1612976400@thebiocalendar.com
SUMMARY:Biotech\, Health & Science Career Fair
DESCRIPTION:Brandeis University was founded in 1948 by the American Jewish community at a time when Jews and other ethnic and racial minorities\, and women\, faced discrimination in higher education. \nBrandeis’ visionary founders established a nonsectarian research university that welcomed talented faculty and students of all backgrounds and beliefs. From the outset\, Brandeis focused on undergraduate education\, while building a pioneering research enterprise. \nThe university was named for Louis Dembitz Brandeis (1856-1941)\, the first Jewish justice of the U.S. Supreme Court. One of the greatest minds to serve on the high court\, Justice Brandeis made an indelible mark on modern jurisprudence by shaping free speech\, the right to privacy and the rights of ordinary citizens. He exemplified the values of the new university through his dedication to open inquiry and the pursuit of truth\, insistence on critical thinking\, and his commitment to helping the common man. \nBrandeis University opened on the site of the former Middlesex University in Waltham\, Massachusetts\, with 107 students and 13 faculty members. Under the leadership of founding president Abram L. Sachar\, Brandeis grew quickly in size and scholarly influence\, joining the ranks of the most respected research institutions while still very young. \nIn 1959\, in one of many firsts\, Brandeis launched the Heller School for Social Policy and Management\, the first school of its kind to bridge the gap between social welfare and social policy. Heller is consistently ranked by U.S. News & World Report as a “top ten” school of social policy. \nIn 1961\, only 13 years after its founding\, Brandeis won Phi Beta Kappa accreditation\, a distinction fewer than 10 percent of U.S. colleges and universities earn. \nThe same year\, Brandeis established the Rose Art Museum\, whose legendary first curator\, Sam Hunter\, built a permanent collection of works by artists destined to become 20th-century icons. The Rose quickly became a premier educational and cultural institution dedicated to modern and contemporary art. The collection includes important works by Andy Warhol\, Roy Lichtenstein\, Helen Frankenthaler\, Jack Whitten and other giants of modern art. \nIn 1985\, Brandeis was elected to the Association of American Universities\, an invitation-only group representing 65 of the most prominent research universities in the U.S. and Canada. \nIn 1992\, the Rabb School of Continuing Studies was launched\, offering opportunities for professional development and lifelong learning through innovative courses for on campus and online learners. \nBrandeis International Business School was established in 1994 as the Graduate School of International Economics and Finance\, and in 2003\, became known as Brandeis IBS. The school prepares exceptional individuals from around the world to become principled global professionals. \nSince its early days\, Brandeis has been a top tier university with global reach\, attracting students and faculty from around the world to pursue learning and scholarship at the highest levels. Ours is a community rooted in purpose\, guided by our founding values\, poised to lead in education and research in the 21st century.
URL:https://thebiocalendar.com/event/biotech-health-science-career-fair/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2020/10/download-4.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210216
DTEND;VALUE=DATE:20210219
DTSTAMP:20260514T021435
CREATED:20201111T002455Z
LAST-MODIFIED:20201111T002456Z
UID:1365-1613433600-1613692799@thebiocalendar.com
SUMMARY:Molecular Medicine Tri-Conference
DESCRIPTION:Unprecedented Year – Discuss at Tri-Con 2021! \nOver the past 27 years\, Molecular Medicine Tri-Conference has served as the leading international meeting place for the precision medicine community. As we face the unprecedented task of fighting this pandemic and working together while maintaining social distancing\, Cambridge Healthech Institute once again takes the leadership role of bringing together the life science community at the Tri-Con Virtual 2021. Join international thought leaders to discuss the latest research and technologies in COVID-19 diagnostics\, vaccines and biotherapeutics\, point-of-care diagnostics\, biomarkers and liquid biopsy\, data analytics and artificial intelligence. In addition to the leading research and technology presentations you have come to expect at the Tri-Con\, now available for on-demand viewing\, we have added interactive panel discussions and structured networking opportunities\, for a comprehensive 3-day program designed to maximize collaboration and innovation… all without leaving your computer.
URL:https://thebiocalendar.com/event/molecular-medicine-tri-conference/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210216
DTEND;VALUE=DATE:20210219
DTSTAMP:20260514T021435
CREATED:20210208T160000Z
LAST-MODIFIED:20210218T042439Z
UID:745-1613433600-1613692799@thebiocalendar.com
SUMMARY:BIO CEO & Investor Digital Conference
DESCRIPTION:For more than 20 years\, the BIO CEO & Investor Conference has fueled biotech industry networking with premier investor and banking communities\, focused on established and emerging publicly traded and select private biotech companies. \nThe virtual 2021 event\, taking place February 16-18\, will showcase the Biotechnology Innovation Organization’s (BIO) perspective on the new U.S. Congressional agenda\, the record setting pacing of biotech IPOs and the hottest clinical developments and industry catalysts. \nBuild on the momentum from JPM Week and experience the best of biotech with three-days of productive BIO One-on-One Partnering meetings with institutional investors\, industry analysts\, and senior business development executives seeking potential investments and deal partners.
URL:https://thebiocalendar.com/event/biotechnology-innovation-organization/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2020/10/BIO_Logo_Horizontal_4C.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20210216T120000
DTEND;TZID=America/Los_Angeles:20210216T133000
DTSTAMP:20260514T021435
CREATED:20210121T023930Z
LAST-MODIFIED:20210121T023930Z
UID:1689-1613476800-1613482200@thebiocalendar.com
SUMMARY:PBSS Free Online Symposium: Oxbryta ® (Voxelotor) Tablets for Sickle Cell Disease: The R&D Journey and Lessons Learned
DESCRIPTION:Building upon nearly 70 years of research in sickle cell disease (SCD) pathology\, voxelotor\, an HbS polymerization inhibitor\, was developed to treat\nthe root cause of SCD pathophysiology. In 2019\, the FDA granted Oxbryta® (Voxelotor) accelerated approval using hemoglobin\, a biologic surrogate endpoint\, indicative of reduced SCD hemolysis. In this presentation\, we will share the R&D journey of Oxbryta®. \nThis presentation is part of the symposium series “Success Stories of Recently Approved Drugs and Lessons Learned”\, jointly organized by PBSS and CLSA (California Life Science Association)
URL:https://thebiocalendar.com/event/pbss-free-online-symposium-oxbryta-voxelotor-tablets-for-sickle-cell-disease-the-rd-journey-and-lessons-learned/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2021/01/PBSS-logo-SFBayai-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210217T080000
DTEND;TZID=UTC:20210217T170000
DTSTAMP:20260514T021435
CREATED:20210217T231307Z
LAST-MODIFIED:20210217T231307Z
UID:1814-1613548800-1613581200@thebiocalendar.com
SUMMARY:T+B+M: Re-starting in the New Bio-Economy
DESCRIPTION:oin Biocom\, Jones Day\, and Deloitte for the next installment of the TECH+BIOTECH+MEDTECH (T+B+M) Virtual Series. \nPlease join us to hear remarks from Dr. Ira Kalish followed by a fireside chat with Joe Panetta\, CEO Biocom\, assessing the economic outlook and trends for 2021 as the U.S. and the world seek to emerge from COVID toward economic recovery. \nDr. Kalish will comment on what we may expect in terms of economic policies and programs from the new Administration\, the long-term impact of COVID on the life sciences and technology business sectors\, potential for job growth\, and long-term effect of low interest rates. You won’t want to miss this insightful program! \nLearn more about our TECH+BIOTECH+MEDTECH community and other upcoming events here. \nPresented By: Ira Kalish\, Ph.D.\, Chief Global Economist\, Deloitte Touche Tohmatsu Ltd. \n \nDr. Ira Kalish is the Chief Global Economist of Deloitte Touche Tohmatsu Ltd. He is a specialist in global economic issues as well as the effects of economic\, demographic\, and social trends on the global business environment. He has written about the economies of Western Europe\, Eastern Europe\, Southeast Asia\, China\, Japan\, Mexico and South America\, and has also written extensively on global consumer markets. \nDr. Kalish is the principal author and editor of Deloitte’s Weekly Global Economic Update. In addition\, his other publications include the annual Global Powers of Retailing report; China and India: Comparing the World’s Hottest Consumer Markets; China and India: The Reality Beyond the Hype\, Budget Deficits: Why All the Fuss\, an article in CFO Journal\, and Mind The Gap\, an article in Deloitte Review on changing income distribution. \nDr. Kalish advises Deloitte clients as well as Deloitte’s leadership on economic issues and their impact on business strategy. In addition\, he has given numerous presentations to corporations and trade organizations on topics related to the global economy. Dr. Kalish also serves on the BIAC Economic Policy Committee which advises the OECD on macroeconomic policy issues. He is widely traveled and has given presentations in 47 countries on six continents. \nDr. Kalish has been widely quoted in the news media; his remarks have been published by the Wall Street Journal\, The Economist\, The Financial Times\, USA Today\, The Washington Post\, and U.S. News & World Report. He has appeared on CNN\, CBS News\, CNBC\, PBS and BBC World Service. \nPrior to his work at Deloitte\, Dr. Kalish was chief economist at Retail Forward\, a director at PwC\, vice president at Bankers Trust\, corporate economist at the Eastman Kodak Company\, and researcher at the Institute for International Economics. \nDr. Kalish holds a bachelor’s degree in economics from Vassar College and a PhD in international economics from Johns Hopkins University. He lives in Santa Monica\, CA with his wife and daughters. \nPresented By: Joe Panetta\, President and Chief Executive Officer\, Biocom Board of Directors \n \nPresident and Chief Executive Officer\, Member\, Biocom Board of Directors — San Diego \nAs the leading advocate for the life science industry in California\, President and CEO Joe Panetta guides Biocom by setting strategic direction\, guiding policy priorities\, and championing the biopharmaceutical industry at the local\, state\, national\, and international level. \nMr. Panetta holds a Bachelor of Science degree in biology from LeMoyne College\, and a Master of Public Health degree in industrial and environmental health from the University of Pittsburgh. He is a graduate of the Brookings Institution Program for Executives and the Harvard Program on Negotiation. \nSponsored By: \n \n \nSpecial Thanks To: \n \n\n\n\nPrice of Admission\n\n\n\n\n\n\n\nBiocom Member \nToday’s Price: $0.00\n\n\n\n\n\n\n\n\n\n\n\n\nNon-Member \nToday’s Price: $25.00\n\n\n\nWhere: \nLive Webinar \nBiocom\, Virtual Event \n\n\n\n\nREGISTER
URL:https://thebiocalendar.com/event/tbm-re-starting-in-the-new-bio-economy/
LOCATION:PA
CATEGORIES:Featured
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210218T113000
DTEND;TZID=UTC:20210218T133000
DTSTAMP:20260514T021435
CREATED:20210218T195200Z
LAST-MODIFIED:20210218T195200Z
UID:1852-1613647800-1613655000@thebiocalendar.com
SUMMARY:Fisher Scientific Safety Webinar
DESCRIPTION:Important: You must be a current Fisher Scientific Safety Customer to attend. An exclusive discount will be offered to customers during the event on a select number of items. \nJoin Fisher Scientific for a virtual\, exclusive safety event with 15 of their top suppliers and specialists focusing on safety\, cleanrooms\, and first response. You’ll be able to join product demonstrations\, live presentations\, interactive question and answer sessions\, and more. \nPlus\, you can talk one on one with a Fisher Scientific safety specialist who can answer your technical questions and help you find solutions for all your safety needs. And after the event\, you’ll receive a discount for use on fishersci.com.
URL:https://thebiocalendar.com/event/fisher-scientific-safety-webinar/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210223
DTSTAMP:20260514T021435
CREATED:20210218T195454Z
LAST-MODIFIED:20210218T195454Z
UID:1853-1613952000-1614038399@thebiocalendar.com
SUMMARY:From the Laboratory to Leadership
DESCRIPTION:From the Laboratory to Leadership turns science-minded managers into capable business leaders. That means they’ll get the core management skills they need to fully leverage your company’s human capital. \nIn this four-day program\, developed exclusively for managers in scientific fields\, participants will learn how to … \n-Create productive teams in a challenging matrix-based team environment \n-Clearly communicate goals and expectations resulting in a highly engaged and productive workforce \n-Run effective meetings that drive results and minimize the time away from your employees highest payoff activities \n-Resolve conflict and reduce stress through an increased understanding of personality and work styles \n-Leverage limited resources to meet major milestones \n-Delegate with confidence while better utilizing your resources and talent \n-Conduct performance reviews and motivate employees through clear communication\, employee development plans\, and the celebration of successes. \nThe program includes company and industry-relevant case studies\, practical and engaging exercises\, down-loadable support tools for each session\, and a manual designed to personalize the training for each participant. \nAdd it all up\, and From the Laboratory to Leadership brings out the best in your managers – which brings out the best performance from your company. It’s no wonder this program has served more than 6\,500 scientific and engineering managers from 600 life science and technology organizations\, including Bio-Rad Laboratories\, Axio Research\, Sutro Biopharma\, DuPont Industrial Biosciences\, Genomatica\, Novozymes\, and Janssen Research and Development\, LLC. \nSyllabus and FAQ’s \nInstructor Bio \n\n\n\nPrice of Admission\n\n\n\n\n\n\n\nMember \nToday’s Price: $2\,795.00\n\n\n\n\n\n\n\n\n\n\n\n\nNon-Member \nToday’s Price: $3\,295.00
URL:https://thebiocalendar.com/event/from-the-laboratory-to-leadership/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210222T120000
DTEND;TZID=UTC:20210222T124500
DTSTAMP:20260514T021435
CREATED:20210218T024648Z
LAST-MODIFIED:20210218T024719Z
UID:1830-1613995200-1613997900@thebiocalendar.com
SUMMARY:The COVID “Next Normal”: Lessons from the NBA Bubble and Vaccine Modeling
DESCRIPTION:As the coronavirus pandemic enters a new phase\, science that can guide vaccination prioritization and business’ return-to-work strategies are more important than ever. In this webinar\, we will explore the experience of the NBA bubble\, in which players were sequestered at the Walt Disney World Resort. Data from this longitudinal testing program has important implications for our understanding of the natural history of SARS-CoV-2 infection and the utility of frequent testing strategies.  In addition\, we will discuss modeling studies that compare different prioritization strategies for COVID vaccination\, and their implications for public health policy. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nRegister for Webinar\n\n\n\n\n\n\n\n\n\n\n\nAbout the Presenter\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nYonatan Grad\, MD\, PhD\n\n\nMelvin J. and Geraldine L. Glimcher Associate Professor\, Department of Immunology and Infectious Diseases\, Harvard TH Chan School of Public Health\nMember of the Division of Infectious Diseases at Brigham and Women’s Hospital\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nYonatan Grad\, MD\, PhD is the Melvin J. and Geraldine L. Glimcher Associate Professor in the Department of Immunology and Infectious Diseases at the Harvard TH Chan School of Public Health\, and a member of the Division of Infectious Diseases at Brigham and Women’s Hospital. He earned his MD and PhD at Harvard Medical School\, trained in internal medicine at BWH and infectious diseases at BWH and Massachusetts General Hospital and did his postdoctoral work in the Center for Communicable Disease Dynamics at the Chan School. The Grad laboratory studies how pathogens evolve and spread through populations with the motivation of improving clinical and public health strategies for decreasing the burden of disease\, with a particular focus on antibiotic resistance. The lab uses a variety of methods\, including genomics\, epidemiological tools and microbiology to define the dynamics of spread and characterize the genotypic and phenotypic diversity of the pathogens. His work on COVID-19 has included working on the MA COVID-19 task force\, advising the NBA on the 2019-20 season restart\, and research on viral trajectory during infection\, spread within NYC\, statistical frameworks for serological studies\, projections of the pandemic and vaccine prioritization strategies\, among others.
URL:https://thebiocalendar.com/event/the-covid-next-normal-lessons-from-the-nba-bubble-and-vaccine-modeling/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210227
DTSTAMP:20260514T021435
CREATED:20210218T011512Z
LAST-MODIFIED:20210218T011512Z
UID:1821-1614038400-1614383999@thebiocalendar.com
SUMMARY:The Conference Forum: Immuno-Oncology 360˚ Summit
DESCRIPTION:IO360˚convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers. \n2021 Keynotes:\n– Padmanee Sharma\, MD\, PhD\, MD Anderson Cancer Center\n– Elizabeth Marion Jaffee\, PhD\, Johns Hopkins University\n– Lisa Butterfield\, PhD\, Parker Institute for Cancer Immunotherapy\n– Andrew Baum\, MD\, Citi\n– Kole Roybal\, PhD\, University of California\, San Francisco\n– John Reed\, MD\, PhD\, Sanofi \n2021 Key Topics:\n– Discovery/Preclinical Science\n– Cell & Gene Therapy\n– Translational Science\n– Bispecifics\n– Clinical Developments\n– Neoadjuvant/Adjuvant Data\n– Emerging Biomarkers\n– Vaccines\n– Clinical Operations\n– AI & Machine Learning\n– Imaging Aspects\n– Business Developments \n10% Discount with code CLSA10\nwww.io360summit.com \nClick Here for More Information
URL:https://thebiocalendar.com/event/the-conference-forum-immuno-oncology-360%cb%9a-summit/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20260514T021435
CREATED:20210223T080000Z
LAST-MODIFIED:20210217T231657Z
UID:557-1614038400-1614297599@thebiocalendar.com
SUMMARY:Biocom’s Global Life Science Partnering Conference
DESCRIPTION:THE PREMIER VIRTUAL PARTNERING EVENT OF 2021\nBiocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration\, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner. \nBiocom’s 11th Annual Global Life Science Partnering Conference will be completely virtual and is an exclusive global partnering forum that brings together senior executives\, bankers\, venture capitalists\, and business development professionals from leading pharmaceutical and biotech companies. Join us February 23rd to 25th\, 2021\, where industry leaders will debate current trends\, companies will showcase their latest technologies and all attendees will have the opportunity to schedule one-on-one meetings with leading deal-makers. \nThe partnering conference and the relationships you build promise to be fruitful for your business ventures this year and for many years to come. We are excited by the prospect of continuing an annual bio-pharma partnering conference that brings together leading deal makers and emerging biotechs from around the world. \nJoin us in February 2021\, where industry leaders will debate current trends\, companies will showcase their latest technologies and all attendees will have the opportunity to schedule virtual one-on-one meetings with leading dealmakers from around the globe. \n\nAttendee Benefits: \n\nConnect Globally\, Virtually with  500+ Attendees\n800+ One-on-One Partnering Meetings\nPanel Discussions with Industry Thought Leaders from Around the Globe\nFireside Chats from Industry Luminaries\nKeynote Presentations\nContinued Access to Emerging Companies Seeking Funding and Partnerships Even After the Conference Ends\nPrivate Access to Recorded Keynotes\, Panel Discussions and Company Presentation Content\n\nHear What Others Have to Say: \n“Every partnering meeting was great and all the panels were beyond fantastic. I even met a new investor!”\nRoss Bundy\, CEO\, Nanomedical Diagnostics \n“Presenting at Biocom this year helped put Forge on the radar of several investors seeking to put money to work in the antibiotic space. The conference not only gave me the opportunity to meet the interested investors face-to-face but also gave me a platform to describe our funding strategy and growth trajectory\, which gave us additional momentum leading to upsizing our Series A round. In fact\, after my presentation multiple investors that were ‘circling the hoop’ were now ready to jump into the game and asked if they could participate in the Series A financing.”\nZachary Zimmerman\, Ph.D.\, CEO \, Forge Therapeutics\, Inc.
URL:https://thebiocalendar.com/event/biocoms-global-life-science-partnering-conference/
LOCATION:PA
CATEGORIES:Featured
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2020/09/servlet-8-e1600875244655.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210227
DTSTAMP:20260514T021435
CREATED:20210223T080000Z
LAST-MODIFIED:20201029T201534Z
UID:744-1614038400-1614383999@thebiocalendar.com
SUMMARY:Immuno-Oncology 360 Degree
DESCRIPTION:IO360˚convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.\n\n \nThe 7th Annual Immuno-Oncology 360° Delivers Three Key Benefits: \n\nAccess to KOLs driving the science\nPartnership opportunities with all stakeholders in Immuno-Oncology\nPresentations on the latest data affecting the science\, clinical and business advancements in Immuno-Oncology\n\n\n2021 Strategic Leadership\n\n\n\n2021 Plenary Topics\n\n\n\n\n\nDiscovery/Preclinical Science\n\n\n\n\nCell & Gene Therapy\n\n\n\n\n\n\nTranslational Science\n\n\n\n\nClinical Developments\n\n\n\n\n\n\nEmerging Biomarkers\n\n\n\n\nBispecifics\n\n\n\n\n\n\nClinical Operations\n\n\n\n\nAI & Machine Learning\n\n\n\n\n\n\nImaging Aspects\n\n\n\n\nBusiness Developments\n\n\n\n\n\n\n\n\n  \n\nVideo Player
URL:https://thebiocalendar.com/event/immuno-oncology-360-degree/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2020/10/download.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210224
DTEND;VALUE=DATE:20210226
DTSTAMP:20260514T021435
CREATED:20201003T005756Z
LAST-MODIFIED:20201107T005438Z
UID:794-1614124800-1614297599@thebiocalendar.com
SUMMARY:Precision In Clinical Trials Virtual Summit (West Coast) Feb 24th-25th 2021
DESCRIPTION:Join us at PCT West Coast for a two-day journey into the insightful world of clinical trials. You’ll connect with an incredible gathering of experts and uncover practical advice from industry-leading researchers\, peers and executives. Get ready for an event designed to deliver real value-packed insights\, connections with fellow professionals and learn strategies you can put to use the very next day. \nPEG is excited to announce our third USA Precision in Clinical Trials summit series is coming to the West Coast virtually in Febuary. The Precision in Clinical Trials summit will be a unique platform for the largest bio-pharmaceutical hub in the region to network and discuss collaboration in order to achieve their outsourcing and operational strategies. \nThe summit is tailor-made to address the concerns of trial sponsors who are conducting clinical trials at a local and global level. With an innovation focused agenda\, pre-scheduled meetings between potential collaborators and a host of reliable solution providers\, the summit is designed to help attendees find solutions to their most pressing clinical trial challenges in 2021 and beyond.
URL:https://thebiocalendar.com/event/precision-in-clinical-trials-summit-san-francisco/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2020/10/precision_evolution_global_1584508297.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210224T160000
DTEND;TZID=UTC:20210224T190000
DTSTAMP:20260514T021435
CREATED:20210218T025040Z
LAST-MODIFIED:20210218T025040Z
UID:1831-1614182400-1614193200@thebiocalendar.com
SUMMARY:BioXchange Sponsored by Renovo Solutions
DESCRIPTION:Miss being able to network with colleagues in the life science industry? We have you covered with the best virtual networking experience through Grapevine Network‘s networking platform. Connect with life science colleagues from all over the world. This month’s event will be sponsored by RENOVO Solutions. \nBioXchange has gone virtual to allow the best online opportunity to interact with individuals from throughout the life science industry. The event will be hosted on Grapevine Network‘s platform which provides an amazing experience that allows attendees the freedom to navigate between different group discussions within an interactive chatroom environment. The platform provides the closest experience to a live networking experience. \nParticipants are welcome to join the event at any point of time. The event is subject to run later than the end time posted as the room will stay open as long as people are actively engaged within the chat room.\n***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform. \n  \n\n\n 
URL:https://thebiocalendar.com/event/bioxchange-sponsored-by-renovo-solutions/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210225
DTEND;VALUE=DATE:20210226
DTSTAMP:20260514T021435
CREATED:20210218T211830Z
LAST-MODIFIED:20210218T211923Z
UID:1866-1614211200-1614297599@thebiocalendar.com
SUMMARY:First in class Hit Finding\, the In-Silico Way
DESCRIPTION:A show case of our computational chemistry capabilities with emphasis on virtual screening and scaffold-hopping campaigns for first-in-class targets\, demonstrated through scientific case studies. Application of latest Machine-learning algorithms to various end-points. Insights into Jubilant Biosys’ current ML model development\, as a platform\, for CardioTox\, including individual classification models for hERG\,Nav1.5 and Cav1.2 and many more similar models through the value chain. \nSpeakers\n\n \n\nRajendra Kristam\nPrincipal Scientist\, Computational Chemistry @Jubilant Biosys Limited\nRajendra has more than 17 years’ experience in Traditional and Computational Chemistry\, beginning his career with Eli Lilly Research Centre\, Windlesham\, UK. Before joining us he worked with Aurigene Discovery Technologies and has been associated with Jubilant Biosys for the last 14 years. Rajendra holds MSc. Chemistry from University of Hyderabad and MSc. Chemoinformatics from University of Sheffield\, Sheffield\, UK. He has a MBA (Marketing) from Osmania University\, Hyderabad\, many research articles and patents to his credit. Rajendra heads the computational chemistry function at Jubilant Biosys and leads his team to support drug discovery projects. He has guided many virtual screening campaigns and scaffold-hopping efforts for hit-identification. He has been part of teams that delivered five clinical candidates and other targets too.\n\n\n\n\n \n\nSaurabh Kapure\nVice President – Business Development (US & APAC) @Jubilant Biosys Limited\nSaurabh has over 18 years of experience in corporate and international business development in pharmaceutical and drug discovery contract research organizations\, marketing (product/brand management)\, strategic planning\, alliance and process management. He has worked across various geographies like Europe\, North America and Asia wherein he created and built businesses from scratch. His experience is spread across multiple Indian pharma cos including Torrent Pharma\, Piramal Enterprises and Dr. Reddy’s Laboratories where he worked in various businesses around branded generics and Drug Discovery service providers including Aurigene Discovery\, AMRI Global and Panacea Biotech both in managerial and leadership roles.
URL:https://thebiocalendar.com/event/first-in-class-hit-finding-the-in-silico-way/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210225T120000
DTEND;TZID=America/Chicago:20210225T130000
DTSTAMP:20260514T021435
CREATED:20210216T213740Z
LAST-MODIFIED:20210216T214013Z
UID:1790-1614254400-1614258000@thebiocalendar.com
SUMMARY:5 Reasons Life Science Companies Are Moving to the Cloud
DESCRIPTION:Cloud ERP is faster to implement\, less risky and more affordable than ever before.\nJoin SIKICH on Thursday\, February 25th at 12:00PM CT for\n5 REASONS LIFE SCIENCE COMPANIES ARE MOVING TO THE CLOUD\n\n\n\n\n\n\nRegister Today:\n\n\n\n\n\n\n\nFirst Name *\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nLast Name *\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBusiness Email *\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTitle\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTo our customers: We’ll never sell\, distribute or reveal your email address to anyone. Privacy Policy \n\n\n\n\n\n\n\n\n\n\n\n\n\nDon’t let your technology infrastructure interfere with your mission\n\n\n\nMany life sciences companies\, in the pre-revenue and start-up phase\, think that ERP is too costly and complex for a business of their size. However\, in just a matter of months\, these same companies often find that spreadsheets or accounting solutions like QuickBooks can no longer keep up with the growing demands of their business. \nJoin us on Thursday\, February 25th at 12:00PM CT for 5 Reasons Life Science Companies are Moving to the Cloud. Discover why Life Sciences organizations\, like your company\, are moving their operations to the cloud to eliminate compromises and bottlenecks before they interfere with their company’s mission. \nLearn how Cloud ERP solutions enable you to\n\nFocus on Your Mission\nGrow at Your Pace\nSimplify Compliance\nCentralize Data\nand Obtain Peace of Mind\n\n\nIf you’re in the pre-revenue phase\, considering an equity event\, or moving into clinical trials\, you won’t want to miss this!\nFill out your information above to sign-up or go to: http://learn.sikich.com/five-reasons-life-science-moving-to-cloud
URL:https://thebiocalendar.com/event/5-reasons-life-science-companies-are-moving-to-the-cloud/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210225T180000
DTEND;TZID=UTC:20210225T180000
DTSTAMP:20260514T021435
CREATED:20210217T214035Z
LAST-MODIFIED:20210217T214035Z
UID:1805-1614276000-1614276000@thebiocalendar.com
SUMMARY:5 REASONS LIFE SCIENCE COMPANIES ARE MOVING TO THE CLOUD
DESCRIPTION:Many life sciences companies\, in the pre-revenue and start-up phase\, think that ERP is too costly and complex for a business of their size. However\, in just a matter of months\, these same companies often find that spreadsheets or accounting solutions like QuickBooks can no longer keep up with the growing demands of their business.\nJoin us on Thursday\, February 25th at 12:00PM CT for 5 Reasons Life Science Companies are Moving to the Cloud. Discover why Life Sciences organizations\, like your company\, are moving their operations to the cloud to eliminate compromises and bottlenecks before they interfere with their company’s mission.  \nLearn how Cloud ERP solutions enable you to\nFocus on Your Mission\nGrow at Your Pace\nSimplify Compliance\nCentralize Data\nand Obtain Peace of Mind
URL:https://thebiocalendar.com/event/5-reasons-life-science-companies-are-moving-to-the-cloud-2/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210301
DTEND;VALUE=DATE:20210302
DTSTAMP:20260514T021435
CREATED:20210218T005855Z
LAST-MODIFIED:20210218T005855Z
UID:1816-1614556800-1614643199@thebiocalendar.com
SUMMARY:Leadership EDGE For Women: Executive Presence For Women
DESCRIPTION:Executive Presence for Women in Life Sciences\nExecutive presence is the unique combination of what you bring to the table\, what to do at the moment\, and how you need to show up.  Explore the various traits and behaviors that enhance a leader’s presence in the life sciences industry\, understand how character\, substance\, and style affect a leader’s presence\, and gain clarity on personal presence in three key areas: physical\, communication and emotional presence. \nClick Here for More Information
URL:https://thebiocalendar.com/event/leadership-edge-for-women-executive-presence-for-women/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210301T080000
DTEND;TZID=UTC:20210303T170000
DTSTAMP:20260514T021435
CREATED:20210301T160000Z
LAST-MODIFIED:20201001T220338Z
UID:752-1614585600-1614790800@thebiocalendar.com
SUMMARY:World Immunotherapy Congress
DESCRIPTION:Terrapinn events inspire and transform business\n\n\nWe’ve been sparking ideas\, innovations and relationships that transform business for over 30 years. Using our global footprint\, we bring innovators\, disrupters and change agents together\, discussing and demonstrating the technology\, strategies and personalities that are changing the way the world does business. \nOur world leading events bring scale\, knowledge and gravitas to promote innovation and technology that changes people’s lives. Whether it is solar and renewables in Africa\, education technology in Australia\, payments and e-commerce in Asia\, railways in the Middle East\, orphan drugs in the Americas\, or aviation in Europe\, our events make a difference. \nWe are creative\, organic and customer-focused\, curating content for the specific industry and location of each event. Whether you’re looking to make new connections\, introduce product or inspire change in your industry\, we invite you to join us as agitators of change. \n 
URL:https://thebiocalendar.com/event/world-immunotherapy-congress/
LOCATION:PA
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2020/10/download-7-e1601564599750.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210302
DTEND;VALUE=DATE:20210306
DTSTAMP:20260514T021435
CREATED:20210218T011825Z
LAST-MODIFIED:20210218T011825Z
UID:1822-1614643200-1614988799@thebiocalendar.com
SUMMARY:BIO: Oncology Virtual Partnering
DESCRIPTION:During four days of face to face online meetings\, leading researchers\, top biotechs and biopharmaceutical companies will meet\, network and partner to accelerate oncology pipelines and bring new treatment options to patients worldwide.\nOncology Virtual Partnering is organized by Inova Software & BIO \nClick Here for More Information
URL:https://thebiocalendar.com/event/bio-oncology-virtual-partnering/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Indiana/Indianapolis:20210302T095500
DTEND;TZID=America/Indiana/Indianapolis:20210302T152000
DTSTAMP:20260514T021435
CREATED:20210211T005236Z
LAST-MODIFIED:20210211T025622Z
UID:1760-1614678900-1614698400@thebiocalendar.com
SUMMARY:Free Virtual Conference - Pharmacogenomics & Pharmacovigilance in Precision Medicine
DESCRIPTION:Pharmacovigilance and post-market surveillance are critical tools for following drug efficacy and safety in the general population after approval for therapeutic use.  Drug companies use data collected post-marketing to track number and type of adverse events as well as a host of clinical biomarkers.  Thanks to novel tests and high-throughput platforms\, drug companies and regulatory agencies can gain better insights through more precise vigilance monitoring of clinical data and genetic information. By bringing to bear standard clinical tests with pharmacogenetic profiling\, drug companies can better target patients most likely to respond to the therapy and improve the efficiency and efficacy of delivering drugs to patients.  Come join us to learn how pharmacogenetics can enhance pharmacovigilance by combining genetic and clinical data to focus precision medicine resources on clinical needs. \nIf you are a clinician\, research scientist\, or regulator\, this conference is one you won’t want to miss. Please join us for the world’s most informative conference for precision pharmacogenomics and pharmacovigilance leaders with leaders from academia\, biotech\, pharmaceuticals\, diagnostics\, clinical research\, healthcare and regulatory bodies. \nWe invite you to join us in for the Pharmacogenomics & Pharmacovigilance in Precision Medicine Virtual Summit with a line-up of speakers who will address these points and more: \nClinical data in the era of precision medicine\nGenetics/Genomics Platforms\nProteomics/Protein-based Assays\nThe Economics of drug vigilance based on pharmacogenetics\nPositioning drugs tied to pharmacogenetics for coverage by payers\nTracking and evaluating data through telehealth for rapid collections of vigilance data\nWho should attend: \nExecutives and Decision Makers – CEOs\, CTOs\, CMOs\, and CSOs\nLeaders in clinical biostatistics\nClinical trial planning and operations\nClinical Research\, Development\, Translational Medicine\nPracticing Clinicians\nGenomics/Genetics Analysts\nRegulatory Leaders in Government and Business Affairs groups\nEconomic Planners and Forecasters\nMarketing Leaders\nBusiness Development Managers\nBiotech and Biomedical technology researchers\nGovernment and public support agencies
URL:https://thebiocalendar.com/event/pharmacogenomics-pharmacovigilance-in-precision-medicine/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2021/02/PP-Linkedin-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210303
DTEND;VALUE=DATE:20210305
DTSTAMP:20260514T021435
CREATED:20201003T005814Z
LAST-MODIFIED:20201107T005331Z
UID:795-1614729600-1614902399@thebiocalendar.com
SUMMARY:Precision In Drug Discovery & Preclinical Virtual Summit (West Coast)
DESCRIPTION:Join us at PDDP Virtual West Coast for a two-day journey into the insightful world of drug discovery and preclinical development. You’ll connect with an incredible gathering of experts and uncover practical advice from industry-leading researchers and executives. Get ready for an event designed to deliver real value-packed insights\, connections with fellow professionals and learn strategies you can put to use the very next day. \nPEG is excited to announce our third American Precision in Drug Discovery & Preclinical summit series is coming Virtually in March 2021 to our West Coast Participants. The Precision in Drug Discovery & Preclinical event will be a unique platform for the largest bio-pharmaceutical hub in the region to network and discuss collaboration in order to achieve their discovery and scientific strategies. \nThis virtual gathering will showcase the progress and latest research trends that include new compounds\, drug design\, synthesis methods and technologies that advance the science from leaders in the pharma-biotech and academic spaces. With an innovation-focused agenda\, pre-scheduled meetings between potential collaborators and a host of reliable service providers\, the summit is designed to help attendees find solutions to their most pressing research challenges in 2021 and beyond.
URL:https://thebiocalendar.com/event/precision-in-drug-discovery-preclinical-summit/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2020/10/precision_evolution_global_1584508297.jpg
END:VEVENT
END:VCALENDAR